How Many Patients Complete an Adequate Trial of Donepezil?
- 1 January 2002
- journal article
- research article
- Published by Wolters Kluwer Health in Alzheimer Disease & Associated Disorders
- Vol. 16 (1) , 49-51
- https://doi.org/10.1097/00002093-200201000-00008
Abstract
Pharmacy claims data were used to evaluate medication adherence among 59 new users of donepezil aged 65 to 94 years. The probability (+/- 95% confidence interval) of a new user continuing donepezil at 90 days was.797 +/-.103 and at 180 days was.627 +/-.124. Additionally, 13.9% of those who continued therapy for at least 180 days showed gaps in treatment of six weeks or more. These results suggest that adherence with donepezil could be improved in clinical practice.Keywords
This publication has 6 references indexed in Scilit:
- Open-Label, Multicenter, Phase 3 Extension Study of the Safety and Efficacy of Donepezil in Patients With Alzheimer DiseaseArchives of Neurology, 2001
- Donepezil Improves Cognition and Global Function in Alzheimer DiseaseA 15-Week, Double-blind, Placebo-Controlled StudyArchives of internal medicine (1960), 1998
- A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's diseaseNeurology, 1998
- Guidelines on drug treatments for Alzheimer's diseaseThe Lancet, 1997
- The assessment of refill compliance using pharmacy records: Methods, validity, and applicationsJournal of Clinical Epidemiology, 1997
- Discontinuation of Antihyperlipidemic Drugs — Do Rates Reported in Clinical Trials Reflect Rates in Primary Care Settings?New England Journal of Medicine, 1995